C3 inhibition has the potential to broadly control not only ARDS but also the systemic inflammation affecting the microvascular beds of the kidney, brain and other vital organs, which seems to be a complication in severe cases.
However, complement inhibitors are currently only used in rare human diseases, such as paroxysmal nocturnal haemoglobinuria. In these unprecedented times, we would encourage all complement-dedicated pharmaceutical companies, as well as individual scientists, to actively contribute to our efforts to understand the role of complement in COVID-19.
https://www.nature.com/articles/s41577-020-0320-7#Fig1
انتهای پیام/*